Cortisol Excess in Patients With Primary Aldosteronism Impacts Left Ventricular Hypertrophy

J Clin Endocrinol Metab. 2018 Dec 1;103(12):4543-4552. doi: 10.1210/jc.2018-00617.

Abstract

Context: Primary aldosteronism (PA) represents the most frequent form of endocrine hypertension. Hyperaldosteronism and hypercortisolism both induce excessive left ventricular hypertrophy (LVH) compared with matched essential hypertensives. In recent studies frequent cosecretion of cortisol and aldosterone has been reported in patients with PA.

Objective: Our aim was to investigate the impact of cortisol cosecretion on LVH in patients with PA. We determined 24-hour excretion of mineralocorticoids and glucocorticoids by gas chromatography-mass spectrometry and assessed cardiac remodeling using echocardiography initially and 1 year after initiation of treatment of PA.

Patients: We included 73 patients from the Munich center of the German Conn's registry: 45 with unilateral aldosterone-producing adenoma and 28 with bilateral adrenal hyperplasia.

Results: At the time of diagnosis, 85% of patients with PA showed LVH according to left ventricular mass index [(LVMI); median 62.4 g/m2.7]. LVMI correlated positively with total glucocorticoid excretion (r2 = 0.076, P = 0.018) as well as with tetrahydroaldosterone excretion (r2 = 0.070, P = 0.024). Adrenalectomy led to significantly reduced LVMI in aldosterone-producing adenoma (P < 0.001) whereas mineralocorticoid receptor antagonist therapy in bilateral adrenal patients with hyperplasia reduced LVMI to a lesser degree (P = 0.024). In multivariate analysis, the decrease in LVMI was positively correlated with total glucocorticoid excretion and systolic 24-hour blood pressure, but not with tetrahydroaldosterone excretion.

Conclusion: Cortisol excess appears to have an additional impact on cardiac remodeling in patients with PA. Treatment of PA by either adrenalectomy or mineralocorticoid receptor antagonist improves LVMI. This effect was most pronounced in patients with high total glucocorticoid excretion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Cortex / metabolism
  • Adrenal Cortex / surgery
  • Adrenal Cortex Neoplasms / blood
  • Adrenal Cortex Neoplasms / complications*
  • Adrenal Cortex Neoplasms / therapy
  • Adrenalectomy
  • Adrenocortical Adenoma / blood
  • Adrenocortical Adenoma / complications*
  • Adrenocortical Adenoma / therapy
  • Adult
  • Aldosterone / blood
  • Aldosterone / metabolism
  • Echocardiography
  • Female
  • Follow-Up Studies
  • Heart Ventricles / diagnostic imaging
  • Humans
  • Hydrocortisone / blood*
  • Hydrocortisone / metabolism
  • Hyperaldosteronism / blood
  • Hyperaldosteronism / complications*
  • Hyperaldosteronism / therapy
  • Hypertrophy, Left Ventricular / blood
  • Hypertrophy, Left Ventricular / diagnosis
  • Hypertrophy, Left Ventricular / epidemiology
  • Hypertrophy, Left Ventricular / etiology*
  • Male
  • Middle Aged
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Prevalence

Substances

  • Mineralocorticoid Receptor Antagonists
  • Aldosterone
  • Hydrocortisone